Minimal Residual Disease Testing Market to be Worth $4.45 billion by 2031

There is a growing awareness regarding cancer screening and early diagnosis. This has led to diagnoses of cancer at earlier stages which have increased the survival rates in cancer patients compared to historic cancer patients’ survival rates. This is further supported by the advancements in treatments. These surviving cancer patients are at constant risk of relapse and cancer recurrence. These patients require regular monitoring for the signs of relapses to start early treatment. For instance, according to the International Agency for Research on Cancer the estimated number of new cancer cases are expected to increase to 24.5 million by the year 2030 from 19.2 million cases in 2020.